Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC boosted its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 4.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,859,413 shares of the company's stock after purchasing an additional 84,760 shares during the quarter. Geode Capital Management LLC owned approximately 1.83% of Dyne Therapeutics worth $66,802,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of DYN. SG Americas Securities LLC purchased a new stake in shares of Dyne Therapeutics in the second quarter valued at about $217,000. Nisa Investment Advisors LLC lifted its stake in Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company's stock valued at $26,000 after buying an additional 669 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Dyne Therapeutics by 52.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 311,504 shares of the company's stock valued at $10,993,000 after buying an additional 107,233 shares during the last quarter. Legato Capital Management LLC increased its position in Dyne Therapeutics by 35.3% during the second quarter. Legato Capital Management LLC now owns 15,480 shares of the company's stock worth $546,000 after buying an additional 4,035 shares in the last quarter. Finally, Lisanti Capital Growth LLC raised its holdings in shares of Dyne Therapeutics by 22.5% in the second quarter. Lisanti Capital Growth LLC now owns 106,140 shares of the company's stock worth $3,746,000 after acquiring an additional 19,530 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock traded down $0.31 during trading on Friday, reaching $23.99. 1,456,217 shares of the company's stock were exchanged, compared to its average volume of 1,437,825. The company's 50-day moving average is $29.63 and its two-hundred day moving average is $35.01. Dyne Therapeutics, Inc. has a 52-week low of $11.93 and a 52-week high of $47.45. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of -6.74 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Analysts anticipate that Dyne Therapeutics, Inc. will post -3.45 EPS for the current year.

Insider Activity

In other Dyne Therapeutics news, Director Dirk Kersten sold 40,831 shares of the stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $35.32, for a total transaction of $1,442,150.92. Following the transaction, the director now directly owns 193,296 shares in the company, valued at $6,827,214.72. This represents a 17.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jason P. Rhodes sold 782 shares of the business's stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $33.10, for a total transaction of $25,884.20. Following the completion of the sale, the director now directly owns 15,962 shares of the company's stock, valued at $528,342.20. The trade was a 4.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 87,930 shares of company stock worth $2,968,033 over the last ninety days. Corporate insiders own 20.77% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Robert W. Baird assumed coverage on Dyne Therapeutics in a research note on Friday, December 13th. They set an "outperform" rating and a $46.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and set a $55.00 price target on shares of Dyne Therapeutics in a report on Wednesday, November 13th. StockNews.com downgraded shares of Dyne Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, September 16th. Oppenheimer restated an "outperform" rating and set a $55.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Finally, Royal Bank of Canada began coverage on Dyne Therapeutics in a report on Tuesday, November 26th. They issued an "outperform" rating and a $45.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $50.42.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.